1 / 12

Dna repair drugs market analysis | Coherent Market Insights

Read here the latest updates on the Dna repair drugs market analysis published by the CMI team.<br>

adwaitcoherent
Télécharger la présentation

Dna repair drugs market analysis | Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Marketing Insights https://www.coherentmarketinsights.com/ Market Research & Business Consulting Services Covid-19 Impact Tracker

  2. DNA REPAIR DRUGS MARKET ANALYSIS DNA Repair Drugs Market, by Drug (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), and Others), by Application (Ovarian cancer, Fallopian Tube cancer, Peritoneal cancer, Breast cancer and Gastric cancer) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  3. DNA repair drugs are used in repairing damaged DNA and for treating cancers. DNA damage results in genetic disorders, however the human body has its own mechanisms to correct the DNA sequence. DNA repair drugs such as PARP inhibitors and other DNA repair drugs help to treat diseases with genetic aberrations. The global DNA repair drugs market size was valued at US$ 461.3 Mn in 2017, and is expected to exhibit a CAGR of 32.4% over the forecast period (2018–2026).

  4. Figure 1. Global DNA Repair Drugs Market Value (US$ Mn), by Region, 2018

  5. Increasing incidence of cancer, rising government initiatives to promote awareness for cancer treatment, and expansion strategies by manufacturers to increase and expand their product portfolio in the international markets are factors propelling growth of the global DNA repair drugs market Increasing incidence of cancer is expected to drive the global DNA repair drugs market growth over the forecast period. According to the World Cancer Research Fund International’s report in 2018, breast cancer accounted for the second highest number of cancer cases (2,088,849 new cases) across the globe in 2018. According to GLOBOCAN, 43.6% new cases of breast cancer were registered in Asia Pacific in 2018. Moreover, increasing drug approval by key players in order to address demand for efficient therapeutics, is expected to propel growth of the market over the forecast period. In October 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for Talazoparib (Talzenna) for treating patients with HER2 (negative locally advanced or metastatic breast cancer).

  6. Figure 2. Global DNA Repair Drugs Market Share (%), by Drug Type, (2018-2026)

  7. Rising prevalence of cancer, as well as increasing collaborations and acquisitions by key players is expected to boost the market growth North America is expected to dominate the global DNA repair drugs market over the forecast period owing to increasing incidence of cancer. According to the American Cancer Society, in 2018, an estimated 266,120 new cases of invasive breast cancer were diagnosed in the U.S. Moreover, increasing demand for cancer treatments is expected to drive growth of the DNA repair drugs market in the region. Market players are engaged in research and development activities in order to meet the rising demand DNA repair drugs. In May 2019, Clovis Oncology, Inc., collaborated with Bristol-Myers Squibb Company and Foundation Medicine Inc. to initiate phase II study for evaluating rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometroid ovarian cancer.

  8. Key Players Major players operating in the global DNA repair drugs market are AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

  9. Request Sample Report Request Customization Download PDF Brochure Talk to Analyst Referance: https://www.coherentmarketinsights.com/market-insight/dna-repair-drugs-market-2617

  10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. What We Provide:Customized Market Research AnalysisIndustry Analysis ServicesBusiness Consulting ServicesLong Term Engagement ModelCountry Specific Analysis

  11. Contact Us Mr. Shah Coherent Market Insights Pvt. LTD.Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  12. Thank You Kindly Follow CMI Social Media Profiles for the latest Company Updates. Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related